NKF-ASN工作组建议:不包含种族的GFR统一估算方法
美国国家肾脏基金会(NKF)与美国肾脏病学会(ASN)成立工作组,重新评估种族因素在GFR估算中的应用。工作组系统评估了26种方法后聚焦5种,最终推荐立即在美国所有实验室实施不含种族的CKD-EPI肌酐方程,并促进胱抑素C的常规使用以确认eGFR。
要点
- 推荐美国所有实验室立即采用不含种族的CKD-EPI肌酐方程。
- 建议增加胱抑素C的常规使用,以确认有CKD风险或已患CKD成人的eGFR。
- 鼓励研究新的内源性滤过标志物及消除种族差异的干预措施。
核心结论
- 推荐在美国所有实验室立即实施不含种族的CKD-EPI肌酐方程,并促进胱抑素C的常规使用以确认eGFR。
研究设计与样本
- NKF-ASN成立工作组,历时10个月分阶段评估解决GFR估算中种族使用的方法。
- 工作组识别了26种考虑或不考虑种族的GFR估算方法,经共识聚焦于5种。
- 从检测方法可用性与标准化、实施、人群多样性、性能、临床后果及患者中心性六个属性整体评估每种方法。
主要发现
- 美国成人中超过85%肾功能正常。
- 不含种族的CKD-EPI肌酐方程在开发中包含了多样性,所有美国实验室可立即使用,性能可接受且潜在后果不会不成比例地影响任何群体。
- 联合使用肌酐和胱抑素C比单独使用任一标志物更准确,可支持更好的临床决策。
关键数值与推荐
- 推荐1:美国所有实验室立即实施不含种族变量的CKD-EPI肌酐方程。
- 推荐2:国家层面促进胱抑素C的增加、常规和及时使用,尤其用于确认有CKD风险或已患CKD成人的eGFR;若持续证据支持可接受的性能,应采用不含种族变量的CKD-EPI eGFRcys和eGFRcr-cys方程作为一线检测。
- 推荐3:鼓励并资助关于新的内源性滤过标志物及消除种族和民族差异干预措施的研究。
临床怎么用
- 在美国所有实验室采用不含种族的CKD-EPI肌酐方程报告eGFR。
- 对有CKD风险或已患CKD的成人,增加胱抑素C检测以确认eGFR。
- 关注并参与实施不含种族的统一GFR估算方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the estimation of GFR in the United States and its implications for diagnosis and management of patients with, or at risk for, kidney diseases. PROCESS DELIBERATIONS: The Task Force organized its activities over 10 months in phases to ( 1 ) clarify the problem and evidence regarding eGFR equations in the United States (described previously in an interim report), and, in this final report, ( 2 ) evaluate approaches to address use of race in GFR estimation, and ( 3 ) provide recommendations. We identified 26 approaches for the estimation of GFR that did or did not consider race and narrowed our focus, by consensus, to five of those approaches. We holistically evaluated each approach considering six attributes: assay availability and standardization; implementation; population diversity in equation development; performance compared with measured GFR; consequences to clinical care, population tracking, and research; and patient centeredness. To arrive at a unifying approach to estimate GFR, we integrated information and evidence from many sources in assessing strengths and weaknesses in attributes for each approach, recognizing the number of Black and non-Black adults affected. RECOMMENDATIONS: ( 1 ) For US adults (>85% of whom have normal kidney function), we recommend immediate implementation of the CKD-EPI creatinine equation refit without the race variable in all laboratories in the United States because it does not include race in the calculation and reporting, included diversity in its development, is immediately available to all laboratories in the United States, and has acceptable performance characteristics and potential consequences that do not disproportionately affect any one group of individuals. ( 2 ) We recommend national efforts to facilitate increased, routine, and timely use of cystatin C, especially to confirm eGFR in adults who are at risk for or have CKD, because combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone. If ongoing evidence supports acceptable performance, the CKD-EPI eGFR-cystatin C (eGFRcys) and eGFR creatinine-cystatin C (eGFRcr-cys_R) refit without the race variables should be adopted to provide another first-line test, in addition to confirmatory testing. ( 3 ) Research on GFR estimation with new endogenous filtration markers and on interventions to eliminate race and ethnic disparities should be encouraged and funded. An investment in science is needed for newer approaches that generate accurate, unbiased, and precise GFR measurement and estimation without the inclusion of race, and that promote health equity and do not generate disparate care. IMPLEMENTATION: This unified approach, without specification of race, should be adopted across the United States. High-priority and multistakeholder efforts should implement this solution.
引用
- Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. J Am Soc Nephrol. 2021. PMID: 34556489. doi:10.1681/ASN.2021070988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。